Litigation Details for Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd. (D. Del. 2016)
✉ Email this page to a colleague
Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd. (D. Del. 2016)
| Docket | ⤷ Try a Trial | Date Filed | 2016-03-03 |
| Court | District Court, D. Delaware | Date Terminated | 2018-08-24 |
| Cause | 35:0145 | Assigned To | Gregory Moneta Sleet |
| Jury Demand | None | Referred To | |
| Patents | 6,228,398; 6,902,742; 8,808,740; 9,132,096; 9,265,760; 9,326,982; 9,333,201; 9,339,499; 9,421,200; 9,433,619 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd. (D. Del. 2016)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2016-03-03 | 1 | 14. U.S. Patent Nos. 6,228,398 (“the ’398 patent”), 6,902,742 (“the ’742 patent”), …infringement of United States Patent No. 9,265,760 (“the ’760 patent”) under the Patent Laws of the United States…the ’760 patent under 28 U.S.C. §§ 2201 and 2202. A true and correct copy of the ’760 patent is attached…patients using a method of treatment patented by the ’760 patent prior to its expiration. 23.…patients using a method of treatment patented by the ’760 patent prior to its expiration. 25. | External link to document | |
| 2018-03-16 | 112 | 17 and 19 of U.S. Patent No. 9,265,760 (“the ‘760 patent”) and claim 1 of U.S. Patent No. 9,339,499 (“…leading to the ‘499 patent was filed. (Ex. 2, ‘499 patent at face page.) The ‘499 patent is a continuation…of the ‘760 patent and the patents have near-identical specifications. The ‘499 patent issued on May…Asserted Claims are not patent eligible under the Supreme Court’s two-part test for patent-eligible subject …conventional. For example, each of the patent applications and patents disclosing hydrocodone ER dosage forms | External link to document | |
| 2018-03-16 | 116 | and 19 of U.S. Patent Nos. 9,265,760 (“the ’760 Patent”), and claim 1 of U.S. Patent No. 9,339,499 (“…the ’499 Patent”) (collectively, the “asserted claims” of the “patents-in- suit.”). The patents-in-suit… 1. Patent-Eligible Subject Matter Section 101 provides that a patent may be obtained…claims involve a patent-ineligible concept, because essentially every routinely patent-eligible claim … finding patents not invalid under § 101 as a matter of law). B. The patents-in-suit | External link to document | |
| 2018-03-29 | 127 | 17 and 19 of U.S. Patent No. 9,265,760 (“the ’760 patent”), and claim 1 of U.S. Patent No. 9,339,499 (“…the ’499 patent”) (collectively, the “asserted claims” of the “patents-in- suit.”). The patents-in-suit…Infringement of ’760 Patent Claims 12, 17 and 19 and ’499 Patent Claim 1 ...........… infringe ’760 patent claims 12, 17 and 19 and ’499 patent claim 1.......…infringement of ’760 patent claims 12, 17 and 19 and ’499 patent claim 1 ...... | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
